Trial Profile
An Open-Label, Non-Randomized, Multicenter, Three Stage, Phase 2 Study of S-1 as 2nd Line Therapy for Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIB/Stage IV).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2020
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Nov 2005 New trial record.